JP2016522232A - ヘテロアリール置換されたピラゾール類 - Google Patents

ヘテロアリール置換されたピラゾール類 Download PDF

Info

Publication number
JP2016522232A
JP2016522232A JP2016520443A JP2016520443A JP2016522232A JP 2016522232 A JP2016522232 A JP 2016522232A JP 2016520443 A JP2016520443 A JP 2016520443A JP 2016520443 A JP2016520443 A JP 2016520443A JP 2016522232 A JP2016522232 A JP 2016522232A
Authority
JP
Japan
Prior art keywords
compound
hydrogen
alkyl
general formula
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016520443A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016522232A5 (enExample
Inventor
ヒツチコツク，マーリオン
メンゲル，アンネ
ブリーム，ハンス
ガイスラー，イエンス
ジーマイスター，ゲルハルト
ボネ，ヴイルヘルム
フェルナンデス−モンタルバン，アマウリ・エルネスト
シユレーダー，イエンス
ホルトン，サイモン
メンニング，ウルズラ
Original Assignee
バイエル ファーマ アクチエンゲゼルシャフト
バイエル ファーマ アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイエル ファーマ アクチエンゲゼルシャフト, バイエル ファーマ アクチエンゲゼルシャフト filed Critical バイエル ファーマ アクチエンゲゼルシャフト
Publication of JP2016522232A publication Critical patent/JP2016522232A/ja
Publication of JP2016522232A5 publication Critical patent/JP2016522232A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016520443A 2013-06-21 2014-06-17 ヘテロアリール置換されたピラゾール類 Pending JP2016522232A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13173280.2 2013-06-21
EP13173280 2013-06-21
PCT/EP2014/062694 WO2014202588A1 (en) 2013-06-21 2014-06-17 Heteroaryl substituted pyrazoles

Publications (2)

Publication Number Publication Date
JP2016522232A true JP2016522232A (ja) 2016-07-28
JP2016522232A5 JP2016522232A5 (enExample) 2017-07-20

Family

ID=48651937

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016520443A Pending JP2016522232A (ja) 2013-06-21 2014-06-17 ヘテロアリール置換されたピラゾール類

Country Status (7)

Country Link
US (1) US20160168130A1 (enExample)
EP (1) EP3010911A1 (enExample)
JP (1) JP2016522232A (enExample)
CN (1) CN105452242A (enExample)
CA (1) CA2916109A1 (enExample)
HK (1) HK1223097A1 (enExample)
WO (1) WO2014202588A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
WO2013092512A1 (en) 2011-12-21 2013-06-27 Bayer Intellectual Property Gmbh Substituted benzylpyrazoles
CA2907594A1 (en) * 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft Heteroaryl substituted indazoles
EP3010902A1 (en) * 2013-06-21 2016-04-27 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
US9765058B2 (en) 2013-06-21 2017-09-19 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
HK1223098A1 (zh) 2013-06-21 2017-07-21 Bayer Pharma Aktiengesellschaft 杂芳基取代的吡唑
US9682974B2 (en) 2013-10-30 2017-06-20 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
WO2015089182A1 (en) * 2013-12-11 2015-06-18 Ironwood Pharmaceuticals, Inc. Sgc stimulators
UY36175A (es) 2014-06-17 2016-01-29 Bayer Pharma AG 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
AU2015316796A1 (en) 2014-09-19 2017-03-30 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as Bub1 inhibitors
EA032530B1 (ru) 2015-01-28 2019-06-28 Байер Фарма Акциенгезельшафт 4h-пирроло[3,2-c]пиридин-4-оновые производные
JP2018522847A (ja) 2015-06-17 2018-08-16 バイエル ファーマ アクチエンゲゼルシャフト ３−アミノ−１，５，６，７−テトラヒドロ−４ｈ−インドール−４−オン類
WO2017148995A1 (en) 2016-03-04 2017-09-08 Bayer Pharma Aktiengesellschaft 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity
WO2017157992A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders
WO2017157991A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors
UY39391A (es) * 2020-08-24 2022-03-31 Adama Makhteshim Ltd Proceso para la preparación de pirazoles sustituidos
EP4217070A1 (en) 2020-09-23 2023-08-02 Scorpion Therapeutics, Inc. Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer
WO2022072634A1 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Bicyclic compounds for use in the treatment cancer
WO2022072645A2 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Methods for treating cancer
TW202227063A (zh) 2020-10-09 2022-07-16 美商史考皮恩治療有限公司 治療癌症之方法
WO2022094271A1 (en) 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
WO2022197913A1 (en) 2021-03-18 2022-09-22 Scorpion Therapeutics, Inc. Bicyclic derivatives which can be used to treat cancer
WO2023173083A1 (en) 2022-03-11 2023-09-14 Scorpion Therapeutics, Inc. Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer
WO2024254266A1 (en) 2023-06-08 2024-12-12 Scorpion Therapeutics, Inc. A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer
WO2024254298A1 (en) 2023-06-08 2024-12-12 Scorpion Therapeutics, Inc. A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070179133A1 (en) * 2003-03-14 2007-08-02 David Bebbington Compositions useful as inhibitors of protein kinases
WO2012003405A1 (en) * 2010-06-30 2012-01-05 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2013050438A1 (en) * 2011-10-06 2013-04-11 Bayer Pharma Aktiengesellschaft Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9284298B2 (en) * 2011-04-11 2016-03-15 Nerviano Medical Sciences S.R.L. Pyrazolyl-pyrimidine derivatives as kinase inhibitors
WO2013092512A1 (en) * 2011-12-21 2013-06-27 Bayer Intellectual Property Gmbh Substituted benzylpyrazoles
HK1223098A1 (zh) * 2013-06-21 2017-07-21 Bayer Pharma Aktiengesellschaft 杂芳基取代的吡唑

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070179133A1 (en) * 2003-03-14 2007-08-02 David Bebbington Compositions useful as inhibitors of protein kinases
WO2012003405A1 (en) * 2010-06-30 2012-01-05 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2013050438A1 (en) * 2011-10-06 2013-04-11 Bayer Pharma Aktiengesellschaft Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.

Also Published As

Publication number Publication date
HK1223097A1 (zh) 2017-07-21
CN105452242A (zh) 2016-03-30
US20160168130A1 (en) 2016-06-16
CA2916109A1 (en) 2014-12-24
EP3010911A1 (en) 2016-04-27
WO2014202588A1 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
JP2016522232A (ja) ヘテロアリール置換されたピラゾール類
JP6141866B2 (ja) 置換ベンジルピラゾール類
JP2016525076A (ja) 置換されたベンジルピラゾール類
JP6140170B2 (ja) 過増殖性疾患の処置におけるｂｕｂ１キナーゼ阻害剤として使用するための置換ベンジルインダゾール類
US9745285B2 (en) Heteroaryl substituted pyrazoles
ES2620316T3 (es) Cicloalquenopirazoles sustituidos como inhibidores de BUB1 para el tratamiento del cáncer
JP2016514719A (ja) ヘテロアリール置換インダゾール
JP2016526540A (ja) 置換ベンジルピラゾール
JP2016536311A (ja) ヘテロアリール置換ピラゾール類
JP2016514718A (ja) ３−ヘテロアリール置換インダゾール類
JP2016514717A (ja) ジアミノヘテロアリール置換インダゾール
JP2016522231A (ja) ジアミノヘテロアリール置換ピラゾール類
JP2018503648A (ja) ４Ｈ−ピロロ［３，２−ｃ］ピリジン−４−オン誘導体
JP2018525375A (ja) １ｈ−ピロール−３−アミン類
TW201335150A (zh) 經取代之苯甲基吡唑
HK1226733A1 (en) Heteroaryl substituted pyrazoles

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180327

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181016